Urokinase and dialysis therapy  by Twardowski, Zbylut J.
Kidney International, Vol. 57 (2000), pp. 345–350
LETTERS TO THE EDITOR
catheter dysfunction performed during the hemodialysisUrokinase and dialysis therapy
treatment itself. These urokinase protocols hold promise
and are undergoing clinical trials at several centers” [1].To the Editor: In a recent review by Schwab and
Beathard on hemodialysis catheters, the authors did not We believe this continues to accurately reflect the state
of the art. While the study by Twardowski is indeedacknowledge the value of systemic urokinase infusion to
open clotted catheters [1]. Although they admit that the promising [2], we believe further studies should be done
to confirm the safety and efficacy of this procedure priorinfusion appears to be safe and less expensive than either
fibrin sheath stripping or catheter exchange, they also to recommending its wholesale adoption. Multiple con-
firmatory clinical trials were actively underway prior tostate that the “. . . primary disadvantage lies in the fact
that [the infusion] requires four to six hours of hospital the removal of urokinase from the United States market.
Regional Medicare intermediaries exercise broad dis-observation to facilitate payment for the urokinase.”
As a matter of fact, hospitalization for administration cretion in determining appropriate procedures for reim-
bursement. In our areas of practice (North Carolina andof urokinase is not necessary for reimbursement. We have
used urokinase in our outpatient facility for several years Texas), reimbursement for high-dose urokinase per-
formed as an infusion during the hemodialysis treatmentand recently published our experience [2]. Our protocol
uses two to three hours of infusion of 250,000 IU of uroki- in an outpatient hemodialysis facility had not been ap-
proved. The question is at the current state moot, be-nase during outpatient hemodialysis. Heparin is used
together with urokinase. In addition, the method is less cause there appears to be little likelihood that urokinase
in its present form will return to the North Americanexpensive than catheter stripping or replacement. A ma-
jor advantage of the method is that the patient does not market in the near future. We acknowledge the impor-
tance of thrombolytic therapy applied in the dialysis unitmiss dialysis treatment because blood flow is usually
restored. The patient thus avoids hospitalization and the as opposed to any therapy performed in the hospital.
Indeed, confirmatory studies of Dr. Twardowski’s origi-inconvenience related thereto. Outpatient urokinase is
reimbursed in our region (revenue code # 636, HCPCS nal observation were underway at both of our institutions
prior to withdrawal of urokinase from the North Ameri-#J3367), and there is no reason for the lack of reimburse-
ment in other regions, as the method saves money. can market.
Unfortunately, Abbott Laboratories, Inc. (North Chi- Steve J. Schwab and Gerald Beathard
Duke Medical Center, Durham, North Carolina, USAcago, IL, USA), the only manufacturer of urokinase, has
difficulty in providing a sufficient amount of the drug at
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by Garbar et al [1]. In this large post-mortem study,
the authors propose a staging for amyloidosis based onReply from the authors
immunoperoxidase staining and on the analysis of clini-In response to Dr. Twardowski’s concern, we quote
cal data. The authors, although aware of the cross-sec-directly from our review. “Recently, Twardowski has
tional design, concluded that macrophages are not re-reported a series of high-dose urokinase infusions for
quired to form amyloid fibrils [1], supporting the view
that macrophage infiltration is a secondary phenomenon.
We drew a similar conclusion based on an ultrastructural 2000 by the International Society of Nephrology
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